Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Current issue

Page Path
HOME > Browse Articles > Current issue
11 Current issue
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 42(5); October 2026
Prev issue Next issue
Display
Editorial
Colorectal cancer
Beyond local control: what does a pathological complete response tell us about systemic disease in rectal cancer?
Hyun Gu Lee
Ann Coloproctol. 2026;42(5):489-491.   Published online October 28, 2026
DOI: https://doi.org/10.3393/ac.2026.01655.0236
  • 473 View
  • 29 Download
PDF
Review
Colorectal cancer
Clinicopathologic characteristics and molecular landscape for pseudomyxoma peritonei of appendiceal origin
Taehan Yoon, Su-Jin Shin, Ji Min Lee, Eun Jung Park
Ann Coloproctol. 2026;42(5):492-504.   Published online October 15, 2026
DOI: https://doi.org/10.3393/ac.2026.00031.0004
  • 827 View
  • 32 Download
AbstractAbstract PDF
Pseudomyxoma peritonei (PMP) of appendiceal origin presents a unique challenge in oncology owing to its rarity, varied progression, and complex molecular characteristics. The current standard treatment using cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has shown some success in extending survival rates; however, it is associated with significant physical burdens and high recurrence rates. Advances in understanding the molecular and genetic features, particularly mutations in genes such as KRAS, GNAS, and BRAF, have led to a promising shift toward more targeted and less invasive treatment options, potentially moving beyond the limitations of current therapies. Additionally, novel approaches targeting the tumor microenvironment in PMP have gained traction, given the role of factors such as mucin accumulation, hypoxia, and inflammatory cytokines in sustaining tumor persistence and resistance. Emerging personalized therapies and immunotherapies, particularly targeted treatments and peptide vaccine development for GNAS-mutated cancers, offer the potential to enhance treatment specificity and effectiveness. The challenges of multiomics approaches to capture the complex genomic and epigenomic landscape of PMP highlight the need for individualized optimal treatment in patients with PMP.
Original Articles
Colorectal cancer
Is age just a number? Causal modeling of recurrence risk in rectal cancer
Thanat Tantinam, Pawit Sutharat, Suwan Sanmee, Ekkarin Supatrakul, Jiraporn Khorana, Sunhawit Junrungsee, Kullawat Bhatanaprabhabhan, Boonchai Ngamsirimas, Nataphon Santrakul, Rangsima Thiengthiantham, Punnawat Chandrachamnong, Apichat Tantraworasin
Ann Coloproctol. 2026;42(5):505-514.   Published online October 27, 2026
DOI: https://doi.org/10.3393/ac.2026.00171.0024
  • 505 View
  • 16 Download
AbstractAbstract PDFSupplementary Material
Purpose
Young-onset rectal cancer (YORC) is increasingly common and often presents with aggressive histological features; however, its effect on recurrence remains uncertain. This study aimed to estimate the causal effect of age at diagnosis on recurrence in patients with rectal cancer using advanced causal inference methods.
Methods
This multicenter retrospective cohort study was conducted at 2 university hospitals in Thailand. Patients diagnosed with rectal adenocarcinoma between 2013 and 2022 who underwent curative-intent treatment were included. The primary exposure was age at diagnosis, categorized as YORC (<50 years) or late-onset rectal cancer (LORC; ≥50 years). Confounders were prespecified using a directed acyclic graph and addressed using a confounder composite score. Age was also modeled as a continuous variable using natural splines. The primary outcome was cancer recurrence.
Results
Among 585 patients, 116 (19.8%) had YORC and 469 (80.2%) had LORC. Patients with YORC had fewer comorbidities but more unfavorable histological features than those with LORC. Overall, recurrence occurred in 40.2% of patients and most commonly involved distant metastasis. The estimated average causal effect of age on recurrence was −6.5% (95% confidence interval, −16.6% to 3.5%; P=0.202), indicating that younger age was not associated with an increased risk of recurrence, although a protective effect was not confirmed. Natural spline modeling indicated a nonlinear increase in recurrence hazard with advancing age.
Conclusion
Younger age at diagnosis was not associated with worse recurrence outcomes despite adverse pathological features, and a potential protective association could not be excluded.
Others
Usefulness of yellow enhancement technology in laparoscopic surgery: perspectives of general surgery residents
You Qian Lin, Kai Yun Tan, Frederick H. Koh
Ann Coloproctol. 2026;42(5):515-523.   Published online October 14, 2026
DOI: https://doi.org/10.3393/ac.2026.00514.0073
  • 836 View
  • 30 Download
AbstractAbstract PDFSupplementary Material
Purpose
Yellow enhancement (YE) is an image processing technology available in advanced endoscopic and laparoscopic systems. By increasing the contrast of yellow tissue tones, YE is intended to improve tissue differentiation and the identification of dissection planes. However, because YE is a relatively new technology, supporting evidence remains limited. This study qualitatively explored general surgery residents’ perceptions of the usefulness of YE compared with conventional white light imaging and aimed to establish a foundation for developing a qualitatively anchored scoring system for evaluating YE.
Methods
A piloted online survey was electronically distributed to general surgery residents. After providing basic demographic information, respondents viewed videos with and without YE and then assessed their perceptions of the videos, provided general feedback, and reported their overall opinions of YE. Open-ended responses were coded inductively, followed by reflexive thematic analysis.
Results
A total of 34 responses were obtained. The analysis identified 7 recurring themes related to the utility of YE, including superior visualization for structure identification and enhanced contrast for tissue differentiation. Three recurring themes were noted regarding the limitations of YE, including visual distortion and fatigue, as well as issues related to transition, training, and understanding of YE.
Conclusion
Based on video demonstrations, surgical residents generally perceived YE as beneficial in laparoscopic surgery. However, variability in perceptions highlights the subjective and context-dependent nature of YE. Ultimately, YE should be conceptualized as a specialized adjunct to, rather than a replacement for, conventional white light imaging in laparoscopic surgery.
Colorectal cancer
Oncological outcomes of robotic versus laparoscopic colectomy for colon cancer: a propensity score–matched study focusing on peritoneal recurrence
Takashi Nonaka, Keisuke Noda, Tetsuro Tominaga, Hiroki Katayama, Shintaro Hashimoto, Makoto Hisanaga, Hiroaki Takeshita, Kazuo To, Hidetoshi Fukuoka, Keitaro Matsumoto
Ann Coloproctol. 2026;42(5):524-533.   Published online October 1, 2026
DOI: https://doi.org/10.3393/ac.2026.00213.0030
  • 798 View
  • 32 Download
AbstractAbstract PDFSupplementary Material
Purpose
To compare perioperative and oncologic outcomes between robotic and laparoscopic colectomy for colon cancer, with a focus on peritoneal recurrence, using a propensity score–matched analysis.
Methods
We retrospectively reviewed 591 patients who underwent minimally invasive colectomy for colon cancer between 2016 and 2024. After 1:1 propensity score matching based on age, sex, body mass index, American Society of Anesthesiologists physical status, clinical stage, and procedure, 90 patients in each group were analyzed. Survival outcomes were assessed using Kaplan-Meier methods and competing risk analysis with the Fine-Gray model.
Results
Robotic colectomy showed lower blood loss (median, 10 mL vs. 20 mL; P<0.001), shorter postoperative hospital stay (median, 9 days vs. 11.5 days, P<0.001), and a higher rate of intracorporeal anastomosis (92.2% vs. 24.4%, P<0.001), without prolonging operative time. Disease-free survival was comparable (P=0.519). Locoregional/peritoneal recurrence-free survival was higher in the robotic group (P=0.037); however, competing risk analysis using the Fine-Gray model showed no significant difference in the cumulative incidence of locoregional/peritoneal recurrence between groups. Multivariable analysis identified high-grade histology as an independent predictor of peritoneal recurrence, whereas surgical approach was not.
Conclusion
Robotic colectomy provides favorable perioperative outcomes while maintaining oncologic safety comparable to laparoscopic colectomy. Peritoneal recurrence appears to be driven primarily by tumor biology, and intracorporeal anastomosis does not increase recurrence risk.
Colorectal cancer
Complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer and systemic oncologic benefit: a retrospective cohort study in Korea
Seung Ho Song, Jun Seok Park, Soo Yeun Park, Hye Jin Kim, Sung-Min Lee, Min Kyu Kang, Jong Gwang Kim, An Na Seo, Gyu-Seog Choi
Ann Coloproctol. 2026;42(5):534-544.   Published online October 1, 2026
DOI: https://doi.org/10.3393/ac.2026.00549.0078
  • 761 View
  • 52 Download
  • 1 Web of Science
  • 1 Citations
AbstractAbstract PDF
Purpose
Neoadjuvant chemoradiotherapy (CRT) improves local control in locally advanced rectal cancer (LARC) but has not consistently demonstrated a survival benefit. This study evaluated whether pathological complete response (ypCR) after CRT confers systemic oncological benefit beyond local tumor control.
Methods
A total of 1,105 patients with clinically staged T3 or node-positive rectal cancer who underwent total mesorectal excision at a single tertiary center between 2004 and 2019 were categorized into 3 groups: no CRT (n=608), non-ypCR (n=414), and ypCR (n=83). Primary outcomes were 5-year overall survival (OS) and relapse-free survival (RFS). Secondary outcomes were 5-year cumulative incidences of local recurrence and distant metastasis.
Results
Five-year OS rates were 77.6%, 82.0%, and 95.7% in the no-CRT, non-ypCR, and ypCR groups, respectively. The ypCR group demonstrated superior OS compared with both no-CRT and non-ypCR groups (P=0.001 and P=0.007, respectively). The marginal OS difference between the no-CRT and non-ypCR groups (P=0.047) was no longer significant after multivariable adjustment (hazard ratio, 0.903; P=0.622). Five-year RFS rates were 69.6%, 72.5%, and 91.1% in the no-CRT, non-ypCR, and ypCR groups, respectively. The 5-year cumulative incidence of distant metastasis was lower in the ypCR group (7.5%) than in the no-CRT and non-ypCR groups (23.8% and 25.0%, respectively; P=0.005). On multivariable analysis, ypCR remained independently associated with reduced risks of death, relapse, and distant metastasis.
Conclusion
The ypCR after neoadjuvant CRT in LARC was associated with superior survival and reduced distant metastasis, suggesting effective systemic tumor control rather than a local treatment effect alone.

Citations

Citations to this article as recorded by  
  • Beyond local control: what does a pathological complete response tell us about systemic disease in rectal cancer?
    Hyun Gu Lee
    Annals of Coloproctology.2026; 42(5): 489.     CrossRef
Colorectal cancer
Transverse colon cancer as an independent predictor of locoregional recurrence in patients with stage III colon cancer: a retrospective cohort study
Min Hyeong Jo, Kyong-Min Kang, Mi Jeong Choi, Hye-Rim Shin, Tae-Gyun Lee, Hong-Min Ahn, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang
Ann Coloproctol. 2026;42(5):545-552.   Published online October 1, 2026
DOI: https://doi.org/10.3393/ac.2026.00325.0046
  • 978 View
  • 19 Download
Graphical AbstractGraphical Abstract AbstractAbstract PDF
Purpose
This study aimed to evaluate the significance of transverse colon cancer as a predictor of locoregional recurrence in patients with stage III colon cancer.
Methods
This single-center retrospective cohort study included 1,302 patients who underwent curative-intent laparoscopic colectomy for stage III colon cancer between 2003 and 2021. The primary outcome was locoregional recurrence, defined as tumor recurrence near the anastomotic site, regional lymph nodes, or peritoneal recurrence around the primary tumor. Multivariate analyses were conducted to identify the factors associated with locoregional recurrence.
Results
Transverse colon cancer was identified in 151 patients (11.6%). Baseline characteristics were similar, but transverse colon cancer exhibited a higher locoregional recurrence rate than nontransverse colon cancer (7.9% vs. 2.0%, P<0.001). In transverse colon cancer, locoregional recurrence did not differ according to high ligation of the mid-colic vessel (without high ligation, 10.6% vs. high ligation, 6.7%; P=0.517), and 10 of 12 recurrences (83.3%) occurred predominantly in the regional lymph nodes. In multivariate analysis, transverse colon (hazard ratio [HR], 4.513; 95% confidence interval [CI], 2.226–9.154; P<0.001) and N2 category (HR, 2.044; 95% CI, 1.034–4.042; P=0.040) emerged as independent predictors of locoregional recurrence. Disease-free survival (73.8% vs. 79.2%, P=0.217) and overall survival (84.7% vs. 86.3%, P=0.735) in 5 years were not different between transverse and nontransverse colon cancer.
Conclusion
Transverse colon cancer may serve as an independent predictor of locoregional recurrence in stage III colon cancer. The predominance of regional lymph node recurrence emphasizes the importance of careful regional lymph node assessment in transverse colon cancer.
ERAS
Wearable-measured early postoperative mobility is associated with recovery after elective colorectal cancer surgery: a prospective pilot study
Hyo Jun Kim, Min Jung Kim, Youngjin Kim, Hyun Tae Lim, Jae Hyun Park, Jesung Park, Ji Won Park, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
Ann Coloproctol. 2026;42(5):553-560.   Published online October 27, 2026
DOI: https://doi.org/10.3393/ac.2026.00619.0088
  • 905 View
  • 16 Download
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary Material
Purpose
Early mobilization is a key component of Enhanced Recovery After Surgery (ERAS) pathways following colorectal cancer surgery; however, objective postoperative mobility quantification remains limited. We evaluated whether early postoperative step counts measured using a wearable device could be associated with the achievement of ERAS-based discharge eligibility.
Methods
In this prospective pilot study, adults undergoing elective colorectal cancer resection at a single tertiary academic referral hospital wore a consumer wearable device (Galaxy Watch 5) from the day of surgery. Cumulative step counts on postoperative days (PODs) 1 and 2 were recorded. Discharge readiness was assessed daily by predefined ERAS criteria. The patients were dichotomized according to the median cumulative step count (3,781 steps). The primary endpoint was the achievement of ERAS-based discharge eligibility by POD 3, and the secondary endpoints included time to discharge readiness and postoperative length of stay.
Results
Between August 2023 and December 2024, 38 patients were evaluated. Discharge readiness by POD 3 was more frequent in the active group (68.4% vs. 26.3%; odds ratio, 6.07; 95% confidence interval, 1.49–24.76; P=0.009), which achieved discharge readiness earlier (median, POD 3 vs. POD 4; P=0.003) and had a shorter postoperative stay (median, 5 days vs. 6 days; P=0.041) than did the inactive group. Early diet tolerance differed between the groups (P=0.013).
Conclusion
Higher early postoperative step counts were associated with earlier ERAS-based discharge readiness and shorter hospitalization. Wearable-derived mobility might provide an objective marker of recovery and target for postoperative mobilization strategies.
Technical Note
Anorectal benign disease
Treatment of fecal incontinence and post-fistulotomy "keyhole" deformity with single-site autologous microfat and stromal vascular fraction grafting
André Araújo de Medeiros Silva, Priscilla Ornellas Neves, Carlos Ramon Silveira Mendes, Juliana Gurgel Faria Araújo, Joana Carolina Saraiva de Paula, Marcelo Neves Carvalho, Larissa Martins Peluso
Ann Coloproctol. 2026;42(5):561-565.   Published online October 20, 2026
DOI: https://doi.org/10.3393/ac.2026.00430.0061
  • 516 View
  • 12 Download
PDF
Letters to the Editor
Colorectal cancer
Neoadjuvant chemotherapy in locally advanced colon cancer: lessons from the NeoCol trial and the limits of anatomical risk stratification
Mohamed Alkashty
Ann Coloproctol. 2026;42(5):566-567.   Published online October 15, 2026
DOI: https://doi.org/10.3393/ac.2026.00703.0100
  • 656 View
  • 18 Download
PDF
Technical tips or video clip
Comments on “Mini-invasive J-colpo-perineo-rectopexy with titanized polypropylene mesh for global perineal descent: a technical note”
Alaa Abood Al Wadees
Ann Coloproctol. 2026;42(5):568-570.   Published online October 15, 2026
DOI: https://doi.org/10.3393/ac.2026.00472.0067
  • 435 View
  • 5 Download
PDF
  • FirstFirst
  • PrevPrev
  • Page of 1
  • Next Next
  • Last Last

Ann Coloproctol : Annals of Coloproctology Twitter Facebook
TOP